Erratum: Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: Results from the RA-BUILD study (Annals of the Rheumatic Diseases (2017) 76 (88-95) DOI: 10.1136/annrheumdis-2016-210094);Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: Results from the RA-BUILD study

Annals of the Rheumatic Diseases

Volumn 76, Issue 1, 2017, Pages 88-95

  Dougados, Maxime ^a   Van Der Heijde, Désirée ^b   Chen, Ying Chou ^c,d   Greenwald, Maria ^e   Drescher, Edit ^f   Liu, Jiajun ^g   Beattie, Scott ^g   Witt, Sarah ^g   De La Torre, Inmaculada ^g   Gaich, Carol ^g   Rooney, Terence ^g   Schlichting, Douglas ^g   De Bono, Stephanie ^g   Emery, Paul ^h  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e Desert Medical Advances   (United States)

^f Department of Radiology   (Hungary)

^g ELI LILLY AND COMPANY   (United States)

^h UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BARICITINIB; BILIRUBIN; CREATINE KINASE; CREATININE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ANTIRHEUMATIC AGENT; AZETIDINE DERIVATIVE; JANUS KINASE 1; JANUS KINASE 2; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ADULT; AMERICAN COLLEGE OF RHEUMATOLOGY 20 PERCENT RESPONSE; ANEMIA; ARTHRALGIA; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DAS28; DIGESTIVE SYSTEM PERFORATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HERPES ZOSTER; HUMAN; HYPERTRANSAMINASEMIA; INFECTION; JOINT DESTRUCTION; JOINT STIFFNESS; LUNG TUBERCULOSIS; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE ASSESSMENT; NEUTROPHIL COUNT; NON MELANOMA SKIN CANCER; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIMPLIFIED DISEASE ACTIVITY INDEX; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DIAGNOSTIC IMAGING; MIDDLE AGED; RADIOGRAPHY; RETREATMENT; SEVERITY OF ILLNESS INDEX;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AZETIDINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; JANUS KINASE 1; JANUS KINASE 2; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; RADIOGRAPHY; RETREATMENT; SEVERITY OF ILLNESS INDEX; SULFONAMIDES;

EID: 84991491965     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-210094corr1     Document Type: Erratum

References (31)

1. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016; 75: 3-15.
2. Smolen JS, van der Heijde D, Machold KP, et al. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis 2014; 73: 3-5.
3. O'Shea JJ, Kontzias A, Yamaoka K, et al. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 2013; 72: ii111-15.
4. Keystone EC, Taylor PC, Drescher E, et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 2015; 74: 333-40.
5. Tanaka Y, Emoto K, Tsujimoto M, et al. 12-week results of a phase 2b dose-ranging study of baricitinib, an oral JAK1/JAK2 inhibitor in Japanese patients with rheumatoid arthritis on background methotrexate therapy. Arthritis Rheum 2013; 65: S765.
6. Eli Lilly and Company. A Study in Participants with Moderate to Severe Rheumatoid Arthritis (RA-BEGIN). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US), 2000. (cited 23 May 2016). https://clinicaltrials.gov/show/NCT01711359 NLM identifier: NCT01711359
7. Eli Lilly and Company. A Study in Moderate to Severe Rheumatoid Arthritis (RA-BEAM). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US), 2000 (cited 23 May 2016). https://clinicaltrials.gov/show/NCT01710358 NLM identifier: NCT01710358
8. Eli Lilly and Company. A Study in Moderate to Severe Rheumatoid Arthritis Participants (RA-BUILD). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US), 2000 (cited 23 May 2016). https://clinicaltrials.gov/show/NCT01721057 NLM identifier: NCT01721057
9. Eli Lilly and Company. A Moderate to Severe Rheumatoid Arthritis Study (RA-BEACON). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US), 2000 (cited 23 May 2016). https://clinicaltrials.gov/show/NCT01721044 NLM identifier: NCT01721044
10. Genovese MC, Kremer J, Zamani O, et al. Baricitinib in Patients with Refractory Rheumatoid Arthritis. N Engl J Med 2016; 374: 1243-52.
11. Eli Lilly and Company. An Extension Study in Participants with Moderate to Severe Rheumatoid Arthritis (RA-BEYOND). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US), 2000 (cited 23 May 2016). https://clinicaltrials.gov/show/NCT01885078 NLM identifier: NCT01885078
12. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
13. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
14. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982; 9: 789-93.
15. Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003; 42: 244-57.
16. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23(Suppl. 39): S100-8.
17. Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796-806.
18. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38: 44-8.
19. Disease Activity Score in rheumatoid arthritis. Nijmegen, the Netherlands: University Medical Center. http://www.das-score.nl/das28/ (accessed 28 Apr 2016).
20. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000; 27: 261-3.
21. van der Heijde D. Assessment of radiographs in longitudinal observational studies. J Rheumatol 2004; 31(Suppl 69):46-7.
22. Zhang Y, Warren MS, Zhang X, et al. Impact on creatinine renal clearance by the interplay of multiple renal transporters: a case study with INCB039110. Drug Metab Dispos 2015; 43: 485-9.
23. Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol 2015; 173: 949-61.
24. Takeuchi T, Tanaka Y, Iwasaki M, et al. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomized, double-blind, placebo-controlled phase IIb study. Ann Rheum Dis 2016; 75: 1057-64.
25. Genovese MC, Smolen JS, Weinblatt ME, et al. A randomized phase 2b study of ABT-494, a selective JAK1 inhibitor in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol 2016. doi: 10.1002/art.39808
26. Skoda RC Less Jak2 makes more platelets. Blood 2014; 124: 2168-9.
27. Yamane A, Nakamura T, Suzuki H, et al. Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes. Blood 2008; 112: 542-50.
28. Felson DT, LaValley MP. The ACR20 and defining a threshold for response in rheumatic diseases: too much of a good thing. Arthritis Res Ther 2014; 16: 101.
29. Westhovens R, Alten R, Pavlova D, et al. Filgotinib (GLPG0634), an oral JAK1 selective inhibitor is effective in combination with methotrexate in patients with active rheumatoid arthritis: results from a phase 2B dose ranging study [abstract]. Arthritis Rheumatol 2015; 67(Suppl 10): 1366-7. Abstract number: 1048.
30. Kremer JM, Emery P, Camp HS, et al. A phase 2b study of ABT-494, a selective JAK1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-TNF therapy. Arthritis Res Ther 2016. doi: 10.1002/art.39801
31. Huizinga TW, Fleischmann RM, Jasson M, et al. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomized SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis 2014; 73: 1626-34.